Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

• Status: Completed
• Trial end date: 2006-03-13
• Target enrollment: 0
• Participant gender: All

Summary

A study for patients diagnosed with advanced cutaneous T-cell lymphoma (stage 1B or higher) who have progressive, persistent, or recurrent disease on or following 2 other therapies, one of which must have contained Targretin (bexarotene)or for patients who are not candidates or could not tolerate Targretin therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Vorinostat

Criteria

Inclusion Criteria:

• Patients with Cutaneous T-cell Lymphoma (Stage 1B or higher)

• Age: over 18 years of age

• Have the ability to swallow capsules.

• You must be at least 3 weeks from any prior chemotherapy or anticancer therapy treatment and have recovered from any side effects of that treatment.

• Patients also require adequate heart, liver, and kidney function.

Exclusion Criteria:

• Pregnant and nursing women and those with known allergy to the study drug are excluded from this study.

• Patients are excluded if they are currently receiving chemotherapy, radiation therapy, or other investigational anti-cancer therapy.

• Patients diagnosed with HIV, active hepatitis or who require intravenous antibiotics or antifungal agents are not permitted.